Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rahul Aggarwal

Showing results (181-190 of 223) with videos related to

Pageof 23
Sort By:
Advanced Healthcare Materials|May 3, 2024
Prostate-Specific Membrane Antigen Targeted StarPEG Nanocarrier for Imaging and Therapy of Prostate CancerNiranjan Meher, Gary W Ashley, Kondapa Naidu Bobba, et al.
NPJ Precision Oncology|August 6, 2021
A phase I/II study of rovalpituzumab tesirine in delta-like 3-expressing advanced solid tumorsAaron S Mansfield, David S Hong, Christine L Hann, et al.
Nature Communications|January 3, 2024
Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trialMark C Markowski, Mary-Ellen Taplin, Rahul Aggarwal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 23, 2024
PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19)Rahul Aggarwal, Glenn Heller, David W Hillman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 22, 2026
Synergistic treatment of prostate cancer and multiple myeloma using CD46-targeted radioimmunotherapy-antibody drug conjugatesAnil P Bidkar, Scott Bidlingmaier, Anju Wadhwa, et al.
JAMA Oncology|September 23, 2021
Prognosis Associated With Luminal and Basal Subtypes of Metastatic Prostate CancerRahul Aggarwal, Nicholas R Rydzewski, Li Zhang, et al.
Urologic Oncology|December 17, 2022
Quality of life for men with metastatic castrate-resistant prostate cancer participating in an aerobic and resistance exercise pilot interventionCrystal S Langlais, Yea-Hung Chen, Erin L Van Blarigan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 13, 2025
Effective Treatment of Disseminated Prostate Cancer Using CD46-Targeted 225Ac TherapyAnil P Bidkar, Robin Peter, Anju Wadhwa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 14, 2023
Treatment of Prostate Cancer with CD46-targeted 225Ac Alpha Particle RadioimmunotherapyAnil P Bidkar, Sinan Wang, Kondapa Naidu Bobba, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 23, 2022
CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null DiseaseNing Zhao, Shalini Chopra, Kai Trepka, et al.
Pageof 23

Showing results (181-190 of 223) with videos related to

Sort By:
Pageof 23
Advanced Healthcare Materials|May 3, 2024
Prostate-Specific Membrane Antigen Targeted StarPEG Nanocarrier for Imaging and Therapy of Prostate CancerNiranjan Meher, Gary W Ashley, Kondapa Naidu Bobba, et al.
NPJ Precision Oncology|August 6, 2021
A phase I/II study of rovalpituzumab tesirine in delta-like 3-expressing advanced solid tumorsAaron S Mansfield, David S Hong, Christine L Hann, et al.
Nature Communications|January 3, 2024
Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trialMark C Markowski, Mary-Ellen Taplin, Rahul Aggarwal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 23, 2024
PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19)Rahul Aggarwal, Glenn Heller, David W Hillman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 22, 2026
Synergistic treatment of prostate cancer and multiple myeloma using CD46-targeted radioimmunotherapy-antibody drug conjugatesAnil P Bidkar, Scott Bidlingmaier, Anju Wadhwa, et al.
JAMA Oncology|September 23, 2021
Prognosis Associated With Luminal and Basal Subtypes of Metastatic Prostate CancerRahul Aggarwal, Nicholas R Rydzewski, Li Zhang, et al.
Urologic Oncology|December 17, 2022
Quality of life for men with metastatic castrate-resistant prostate cancer participating in an aerobic and resistance exercise pilot interventionCrystal S Langlais, Yea-Hung Chen, Erin L Van Blarigan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 13, 2025
Effective Treatment of Disseminated Prostate Cancer Using CD46-Targeted 225Ac TherapyAnil P Bidkar, Robin Peter, Anju Wadhwa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 14, 2023
Treatment of Prostate Cancer with CD46-targeted 225Ac Alpha Particle RadioimmunotherapyAnil P Bidkar, Sinan Wang, Kondapa Naidu Bobba, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 23, 2022
CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null DiseaseNing Zhao, Shalini Chopra, Kai Trepka, et al.
Pageof 23